Citizens Reaffirms Market Outperform for Prelude Therapeutics, Sees 31% Upside
Citizens maintained its Market Outperform rating and $3.00 price target on Prelude Therapeutics (PRLD), implying roughly 31% upside from the $2.29 share price. The firm highlighted FDA IND clearance for PRT12396, a solid cash position relative to debt, and compelling preclinical results—while noting a competitive field of mutant-selective JAK2V617F…